VentriPoint Diagnostics

VentriPoint Diagnostics Goodwill

Goodwill of VentriPoint Diagnostics (VPT.V) as of Nov 17, 2026.

Goodwill

-CAD

Last updated:

Goodwill of VentriPoint Diagnostics is 2026 - CAD. Goodwill of VentriPoint Diagnostics was 2025 - CAD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

VentriPoint Diagnostics Stock analysis

What does VentriPoint Diagnostics do? VentriPoint Diagnostics Ltd. develops and commercializes diagnostic tools for heart disease monitoring, focusing on the VentriPoint Medical System (VMS+). The VMS+ uses proprietary Knowledge Based Reconstruction (KBR) technology to create 3D heart models from ultrasound, providing volume and ejection fraction measurements comparable to MRI without requiring MRI scans. The company targets healthcare providers seeking point-of-care solutions for cardiac diagnostics, particularly in cardiology departments and clinics managing heart disease patients. Its applications cover congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The company's products are sold to hospitals and medical facilities that require advanced cardiac imaging tools. VMS+ serves as a diagnostic aid that enhances ultrasound capabilities, eliminating the need for MRI in certain scenarios. The system's ability to visualize all four heart chambers and deliver MRI-equivalent metrics positions it as a cost-effective alternative for institutions aiming to reduce MRI dependency. VentriPoint Diagnostics Ltd. focuses on commercializing these diagnostic tools for heart disease monitoring across multiple clinical segments including cardiology, obstetrics, and oncology support services. VentriPoint Diagnostics Ltd. generates revenue through the sale of its diagnostic tools, specifically the VentriPoint Medical System (VMS+), to healthcare institutions. The VMS+ system is marketed as a point-of-care solution that improves cardiac diagnostics without MRI dependency. Its applications span various heart disease contexts, including congenital conditions, pregnancy-related cardiac monitoring, pulmonary hypertension, and oncology-related cardiotoxicity. The company's commercial strategy centers on providing MRI-equivalent diagnostic capabilities through ultrasound enhancement, targeting medical facilities seeking efficient and accessible cardiac imaging solutions. VentriPoint Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about VentriPoint Diagnostics stock

On Eulerpool you can find the complete historical development of Goodwill VentriPoint Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's VentriPoint Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — VentriPoint Diagnostics

All Key Metrics — VentriPoint Diagnostics